Update on Ultomiris Phase III ALS trial
20 August 2021 07:05 BST Update on CHAMPION-ALS Phase III trial of Ultomiris in amyotrophic lateral sclerosis Alexion is discontinuing CHAMPION-ALS, the global Phase III clinical trial of Ultomiris (ravulizumab) in adults with amyotrophic lateral sclerosis (ALS). This decision is based on the recommendation of the Independent Data Monitoring Committee (IDMC), following their review of data from a pre-specified interim analysis. The IDMC recommended that the trial be discontinued due to lack of efficacy. No new safety findings were observed and the data were